Cadus Corporation (Cadus) is engaged in the purchase of homes and land for purposes of renovation or construction and resale. The Company, through its subsidiaries, owns approximately 12 single-family residential zoned properties in Miami-Dade County, Florida. The Company also owns an approximately one-acre single-family residential zoned vacant lot in East Hampton, New York. The Company is focused on its real estate acquisition, renovation and construction activities in Florida. Cadus Technologies, Inc. is a subsidiary of the Company.
Industry, Sector and Symbol:
- Sector: Finance
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: OTCBB:KDUS
- CUSIP: N/A
- Web: caduscorp.com/
- Market Cap: $31.81 million
- Outstanding Shares: 26,288,000
- 52 Week Range: $0.84 - $1.23
Sales & Book Value:
- Trailing P/E Ratio:
- P/E Growth:
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.54 per share
- Price / Book: 0.79
- EBIDTA: ($753,277.00)
- Return on Equity: -2.15%
- Return on Assets: -2.14%
- Current Ratio: 120.09%
- Quick Ratio: 15.29%
- Average Volume: 10,712 shs.
- Beta: 0.29
Frequently Asked Questions for Cadus (OTCBB:KDUS)
What is Cadus' stock symbol?
Cadus trades on the OTCBB under the ticker symbol "KDUS."
When will Cadus make its next earnings announcement?
Who are some of Cadus' key competitors?
Some companies that are related to Cadus include Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS) and Humanigen (KBIO).
Who are Cadus' key executives?
Cadus' management team includes the folowing people:
- Hunter Clark Gary, President, Chief Executive Officer, Director
- David Blitz, Treasurer, Secretary
- Jack G. Wasserman, Lead Independent Director
- Peter S. Liebert M.D., Independent Director
How do I buy Cadus stock?
Shares of Cadus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cadus' stock price today?
MarketBeat Community Rating for Cadus (OTCBB KDUS)MarketBeat's community ratings are surveys of what our community members think about Cadus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cadus stock can currently be purchased for approximately $1.21.
Consensus Ratings for Cadus (OTCBB:KDUS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cadus (OTCBB:KDUS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cadus (OTCBB:KDUS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cadus (OTCBB:KDUS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cadus (OTCBB:KDUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cadus (OTCBB:KDUS)
Insider Ownership Percentage: 0.10%Insider Trades by Quarter for Cadus (OTCBB:KDUS)
Institutional Ownership Percentage: 0.01%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/1/2014||David Blitz||Treasurer||Buy||5,000||$1.48||$7,400.00|| |
|12/1/2014||James Broach||Director||Buy||3,300||$1.48||$4,884.00|| |
|8/19/2014||Jack Gumpert Wasserman||Director||Buy||10,000||$1.54||$15,400.00|| |
|9/24/2013||Moab Capital Partners Llc||Major Shareholder||Sell||1,452,538||$1.45||$2,106,180.10|| |
|9/10/2013||Moab Capital Partners Llc||Major Shareholder||Sell||16,812||$1.45||$24,377.40|| |
Headline Trends for Cadus (OTCBB:KDUS)
Latest Headlines for Cadus (OTCBB:KDUS)
No headlines for this company have been tracked by MarketBeat.com